Zai Lab Limited (ZLAB) Misses Q3 EPS by 43c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates
November 9, 2022 4:01 PM ESTRevenue of $57.5 million for the third quarter of 2022, representing a 33% increase y-o-y and a 19% increase q-o-q; continued revenue growth led by ZEJULA Regional strategic collaboration for TIVDAK® (tisotumab vedotin) strengthens Zai Labs leadership in developing and providing access to medicine to treat womens cancer in ChinaStrong balance sheet with a cash position of $1.12 billionCompany to host a conference call and webcast on November 10, 2022, at 8:00 a.m. ET
SHANGHAI and CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX:... More
